Genocea Biosciences Company Profile (NASDAQ:GNCA)

About Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences logoGenocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GNCA
  • CUSIP: N/A
  • Web: www.genocea.com
Capitalization:
  • Market Cap: $150.56 million
  • Outstanding Shares: 28,624,000
Average Prices:
  • 50 Day Moving Avg: $4.77
  • 200 Day Moving Avg: $5.55
  • 52 Week Range: $3.28 - $7.29
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.27
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.67 per share
  • Price / Book: 7.85
Profitability:
  • EBIDTA: ($54,720,000.00)
  • Return on Equity: -146.46%
  • Return on Assets: -92.29%
Debt:
  • Debt-to-Equity Ratio: 0.56%
  • Current Ratio: 2.97%
  • Quick Ratio: 2.97%
Misc:
  • Average Volume: 548,736 shs.
  • Beta: 2.29
  • Short Ratio: 4.44
 

Frequently Asked Questions for Genocea Biosciences (NASDAQ:GNCA)

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.08. View Genocea Biosciences' Earnings History.

When will Genocea Biosciences make its next earnings announcement?

Genocea Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Genocea Biosciences.

Where is Genocea Biosciences' stock going? Where will Genocea Biosciences' stock price be in 2017?

4 brokerages have issued 12 month price objectives for Genocea Biosciences' stock. Their predictions range from $12.00 to $40.00. On average, they expect Genocea Biosciences' stock price to reach $21.75 in the next twelve months. View Analyst Ratings for Genocea Biosciences.

What are analysts saying about Genocea Biosciences stock?

Here are some recent quotes from research analysts about Genocea Biosciences stock:

  • 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (8/17/2017)
  • 2. Needham & Company LLC analysts commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017. Given financial constraints, however, mgmt now plans to seek a collaborator prior to initiation of Phase 3 development. We believe this creates meaningful uncertainty for GEN-003 development timelines as well as the stock. Mgmt previously announced a shift in strategic focus from infectious disease to immuno-oncology. However, initial candidate from latter program is not expected to reach clinical development until YE17. We are downgrading to HOLD based on uncertainty around GEN-003 and lack of near-term milestones w/ immuno-oncology program. ATLAS platform holds substantial value and we believe stock remains attractive for long-term investors w/ horizon beyond 2017." (2/17/2017)

Who are some of Genocea Biosciences' key competitors?

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the folowing people:

  • Katrine S. Bosley, Chairman of the Board
  • William D. Clark, President, Chief Executive Officer, Director
  • Jonathan M. Poole, Chief Financial Officer
  • John E. Bishop Ph.D., Executive Vice President - Pharmaceutical Sciences
  • Jessica Baker Flechtner Ph.D., Chief Scientific Officer
  • Seth V. Hetherington M.D., Chief Medical Officer
  • Eric S. Hoffman Ph.D., Chief Business Officer
  • Ronald Harold Wilfred Cooper, Director
  • George Siber M.D., Director
  • Kenneth M. Bate, Independent Director

Who owns Genocea Biosciences stock?

Genocea Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Franklin Resources Inc. (10.51%), Northpointe Capital LLC (4.69%), Vanguard Group Inc. (3.01%), AXA (2.06%) and Sphera Funds Management LTD. (1.72%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jonathan Poole and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.

Who sold Genocea Biosciences stock? Who is selling Genocea Biosciences stock?

Genocea Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., AXA and Dimensional Fund Advisors LP. View Insider Buying and Selling for Genocea Biosciences.

Who bought Genocea Biosciences stock? Who is buying Genocea Biosciences stock?

Genocea Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Northpointe Capital LLC, Vanguard Group Inc., TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Teachers Advisors LLC and California State Teachers Retirement System. Company insiders that have bought Genocea Biosciences stock in the last two years include Eric S Hoffman, Jonathan Poole and William D Clark. View Insider Buying and Selling for Genocea Biosciences.

How do I buy Genocea Biosciences stock?

Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of Genocea Biosciences stock can currently be purchased for approximately $5.26.


MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  160 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Genocea Biosciences (NASDAQ:GNCA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.75 (313.50% upside)

Analysts' Ratings History for Genocea Biosciences (NASDAQ:GNCA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/25/2017Cowen and CompanyReiterated RatingOutperform$40.00HighView Rating Details
7/25/2017Piper Jaffray CompaniesReiterated RatingOverweight$17.00 -> $18.00HighView Rating Details
7/24/2017Needham & Company LLCUpgradeHold -> Buy$12.00HighView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
4/1/2016Stifel NicolausBoost Price TargetBuy$11.00 -> $13.00N/AView Rating Details
(Data available from 9/19/2015 forward)

Earnings

Earnings History for Genocea Biosciences (NASDAQ:GNCA)
Earnings by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Earnings History by Quarter for Genocea Biosciences (NASDAQ GNCA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017($0.51)N/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.54)ViewN/AView Earnings Details
5/4/20173/31/2017($0.54)($0.48)ViewListenView Earnings Details
2/16/2017Q416($0.45)($0.56)ViewN/AView Earnings Details
11/3/2016Q316($0.44)($0.45)ViewN/AView Earnings Details
8/4/2016Q216($0.44)($0.39)ViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.35)$0.24 millionViewN/AView Earnings Details
2/11/2016Q415($0.40)($0.37)$0.22 millionViewListenView Earnings Details
11/5/2015Q315($0.43)($0.37)$0.21 millionViewListenView Earnings Details
8/6/2015Q215($0.51)($0.43)$0.12 millionViewN/AView Earnings Details
5/7/2015Q115($0.57)($0.64)$0.12 millionViewListenView Earnings Details
2/12/2015Q414($0.53)($0.66)$0.31 millionViewListenView Earnings Details
11/6/2014Q314($0.43)($0.53)ViewN/AView Earnings Details
8/6/2014Q2($0.42)($0.41)ViewN/AView Earnings Details
5/6/2014Q114($0.60)($0.76)$0.26 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Genocea Biosciences (NASDAQ:GNCA)
Current Year EPS Consensus Estimate: $-1.98 EPS
Next Year EPS Consensus Estimate: $-1.61 EPS

Dividends

Dividend History for Genocea Biosciences (NASDAQ:GNCA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Genocea Biosciences (NASDAQ:GNCA)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 59.25%
Insider Trades by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Insider Trades by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/24/2017Jonathan PooleCFOSell45,000$6.00$270,000.00View SEC Filing  
11/8/2016Eric S. HoffmanInsiderBuy7,000$3.49$24,430.00View SEC Filing  
11/7/2016Jonathan PooleCFOBuy7,000$3.34$23,380.00View SEC Filing  
11/7/2016William D. ClarkInsiderBuy2,800$3.49$9,772.00View SEC Filing  
5/9/2016Jonathan PooleCFOBuy4,000$3.88$15,520.00View SEC Filing  
12/16/2015William D ClarkCEOBuy3,800$6.45$24,510.00View SEC Filing  
9/1/2015Jessica Baker FlechtnerVPSell2,229$11.35$25,299.15View SEC Filing  
6/19/2015Polaris Venture Management Co.Major ShareholderSell30,004$13.04$391,252.16View SEC Filing  
6/17/2015Polaris Venture Management Co.Major ShareholderSell10,618$13.01$138,140.18View SEC Filing  
6/16/2015Polaris Venture Management Co.Major ShareholderSell46,000$13.24$609,040.00View SEC Filing  
6/1/2015Jessica Baker FlechtnerVPSell2,229$10.52$23,449.08View SEC Filing  
5/1/2015Jessica Baker FlechtnerVPSell2,229$10.21$22,758.09View SEC Filing  
4/1/2015Jessica Baker FlechtnerVPSell2,283$11.77$26,870.91View SEC Filing  
3/17/2015Stephen J HoffmanDirectorBuy700,000$8.25$5,775,000.00View SEC Filing  
2/2/2015Jessica Baker FlechtnerVPSell4,699$8.50$39,941.50View SEC Filing  
9/12/2014Jessica Baker FlechtnerVPSell6,435$12.00$77,220.00View SEC Filing  
9/11/2014Paul GiannascaVPSell4,071$11.84$48,200.64View SEC Filing  
9/10/2014Paul GiannascaVPSell834$12.35$10,299.90View SEC Filing  
9/9/2014Paul GiannascaVPSell2,455$12.43$30,515.65View SEC Filing  
9/8/2014Paul GiannascaVPSell2,970$12.80$38,016.00View SEC Filing  
8/29/2014Paul GiannascaVPSell6,760$12.50$84,500.00View SEC Filing  
8/14/2014Polaris Venture Management Co.Major ShareholderSell9,660$13.01$125,676.60View SEC Filing  
8/12/2014Polaris Venture Management Co.Major ShareholderSell63,794$13.28$847,184.32View SEC Filing  
2/10/2014Plc GlaxosmithklineInsiderBuy143,773$12.00$1,725,276.00View SEC Filing  
2/10/2014Polaris Venture Management Co.Major ShareholderBuy232,820$12.00$2,793,840.00View SEC Filing  
2/10/2014Stephen J HoffmanDirectorBuy250,931$12.00$3,011,172.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Genocea Biosciences (NASDAQ:GNCA)
Latest Headlines for Genocea Biosciences (NASDAQ:GNCA)
Source:
DateHeadline
americanbankingnews.com logoZacks: Brokerages Expect Genocea Biosciences, Inc. (GNCA) Will Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - September 11 at 10:34 AM
americanbankingnews.com logoHead to Head Review: Genocea Biosciences (GNCA) and Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - September 6 at 12:16 AM
americanbankingnews.com logoGenocea Biosciences, Inc. (GNCA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 9:12 AM
americanbankingnews.com logo Brokerages Expect Genocea Biosciences, Inc. (GNCA) to Post -$0.51 Earnings Per Share
www.americanbankingnews.com - August 23 at 10:20 PM
americanbankingnews.com logoZacks Investment Research Upgrades Genocea Biosciences, Inc. (GNCA) to Hold
www.americanbankingnews.com - August 17 at 10:40 PM
americanbankingnews.com logoGenocea Biosciences, Inc. (GNCA) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - August 11 at 10:58 PM
finance.yahoo.com logoGenocea Biosciences Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 7:19 PM
finance.yahoo.com logoGenocea Biosciences reports 2Q loss
finance.yahoo.com - August 9 at 7:19 PM
americanbankingnews.com logoGenocea Biosciences, Inc. (GNCA) Announces Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - August 9 at 5:32 PM
americanbankingnews.com logo Analysts Anticipate Genocea Biosciences, Inc. (GNCA) Will Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - August 5 at 2:22 PM
americanbankingnews.com logoGenocea Biosciences, Inc. (NASDAQ:GNCA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 5 at 8:44 AM
streetinsider.com logoGenocea Biosciences (GNCA) Announces Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes
www.streetinsider.com - July 27 at 12:48 AM
seekingalpha.com logoGenocea Biosciences's (GNCA) Conference Call On Positive GEN-003 Phase 2b Results - Slideshow
seekingalpha.com - July 27 at 12:48 AM
americanbankingnews.com logoGenocea Biosciences' (NASDAQ:GNCA) Outperform Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - July 25 at 11:10 AM
americanbankingnews.com logoGenocea Biosciences, Inc. (GNCA) Receives "Overweight" Rating from Piper Jaffray Companies
www.americanbankingnews.com - July 25 at 11:10 AM
benzinga.com logo18 Biggest Mid-Day Gainers For Monday | Benzinga - Benzinga
www.benzinga.com - July 24 at 8:54 PM
nasdaq.com logoPre-Market Most Active for Jul 24, 2017 : WBMD, NDRM, QQQ ... - Nasdaq
www.nasdaq.com - July 24 at 8:54 PM
streetinsider.com logoGenocea Biosciences (GNCA) Announces Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes - StreetInsider.com
www.streetinsider.com - July 24 at 8:54 PM
finance.yahoo.com logoGenocea Biosciences Inc (GNCA): This Analyst Turns Bullish, Sets $12 Target Price
finance.yahoo.com - July 24 at 8:54 PM
finance.yahoo.com logoCowen Sings the Praises of Genocea Biosciences Inc (GNCA) Following Positive GEN-003 Phase 2b Data
finance.yahoo.com - July 24 at 8:54 PM
americanbankingnews.com logoGenocea Biosciences, Inc. (GNCA) CFO Sells $270,000.00 in Stock
www.americanbankingnews.com - July 24 at 7:29 PM
americanbankingnews.com logoGenocea Biosciences, Inc. (GNCA) Upgraded to "Buy" at Needham & Company LLC
www.americanbankingnews.com - July 24 at 4:50 PM
rttnews.com logoGenocea Reports 12-Month Phase 2b Data For GEN-003 In Genital Herpes
www.rttnews.com - July 24 at 8:56 AM
feeds.benzinga.com logoGenocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes
feeds.benzinga.com - July 24 at 7:38 AM
americanbankingnews.com logoGenocea Biosciences, Inc. (NASDAQ:GNCA) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 11:08 PM
americanbankingnews.com logoGenocea Biosciences, Inc. (GNCA) Expected to Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - July 14 at 11:32 AM
americanbankingnews.com logoGenocea Biosciences, Inc. (GNCA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 11 at 8:26 AM
finance.yahoo.com logoGenocea Added to Russell 3000® and Russell 2000® Indices
finance.yahoo.com - June 26 at 9:32 AM
americanbankingnews.com logo Brokerages Anticipate Genocea Biosciences, Inc. (GNCA) Will Announce Earnings of -$0.46 Per Share
www.americanbankingnews.com - June 20 at 8:16 AM
americanbankingnews.com logoGenocea Biosciences, Inc. (GNCA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 16 at 8:16 AM
americanbankingnews.com logoGenocea Biosciences Inc (GNCA) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - June 6 at 11:02 PM
americanbankingnews.com logoGenocea Biosciences Inc (GNCA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - June 5 at 11:16 PM
seekingalpha.com logoGenocea: Investment Update On ~$6 Biotech 'Busted IPO ... - Seeking Alpha
seekingalpha.com - June 1 at 3:28 AM
americanbankingnews.com logoGenocea Biosciences Inc (GNCA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 31 at 11:24 PM
americanbankingnews.com logoGenocea Biosciences Inc (GNCA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 31 at 12:02 AM
americanbankingnews.com logoGenocea Biosciences Inc (GNCA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 22 at 7:56 AM
americanbankingnews.com logoGenocea Biosciences Inc (GNCA) Short Interest Update
www.americanbankingnews.com - May 16 at 7:20 AM
americanbankingnews.com logoGenocea Biosciences Inc (GNCA) Issues Earnings Results
www.americanbankingnews.com - May 8 at 4:40 PM
finance.yahoo.com logoGenocea Reports First Quarter 2017 Financial Results and Positive Clinical Developments on Lead Candidate GEN-003 in Genital Herpes
finance.yahoo.com - May 4 at 12:07 PM
finance.yahoo.com logoInvestor Network: Genocea Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 12:07 PM
marketbeat.com logoGenocea Biosciences reports 1Q loss
marketbeat.com - May 4 at 9:29 AM
americanbankingnews.com logoZacks: Brokerages Expect Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - May 2 at 12:06 AM
americanbankingnews.com logoGenocea Biosciences (GNCA) Earning Somewhat Critical Media Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 8:02 AM
finance.yahoo.com logoGenocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET
finance.yahoo.com - April 27 at 8:05 AM
americanbankingnews.com logoSomewhat Positive Press Coverage Extremely Likely to Impact Genocea Biosciences (GNCA) Stock Price
www.americanbankingnews.com - April 26 at 8:44 AM
americanbankingnews.com logoGenocea Biosciences Inc (GNCA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 11:05 AM
americanbankingnews.com logoGenocea Biosciences (GNCA) Receives Media Impact Score of -0.22
www.americanbankingnews.com - April 20 at 8:53 AM
americanbankingnews.com logoGenocea Biosciences (GNCA) Receiving Very Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 8:58 AM
finance.yahoo.com logoGenocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes
finance.yahoo.com - April 11 at 12:15 PM
americanbankingnews.com logo Brokerages Anticipate Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 10 at 8:30 PM

Social

Chart

Genocea Biosciences (GNCA) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by MarketBeat.com Staff